Efficacy and safety of recombinant human epidermal growth factor for diabetic foot ulcers: A systematic review and meta-analysis of randomised controlled trials.
diabetic foot ulcer
meta-analysis
recombinant human epidermal growth factor
systematic review
wound closure
Journal
International wound journal
ISSN: 1742-481X
Titre abrégé: Int Wound J
Pays: England
ID NLM: 101230907
Informations de publication
Date de publication:
Aug 2020
Aug 2020
Historique:
received:
18
02
2020
accepted:
02
04
2020
pubmed:
29
4
2020
medline:
3
6
2021
entrez:
29
4
2020
Statut:
ppublish
Résumé
To evaluate the efficacy and safety of recombinant human epidermal growth factor (rhEGF) in treating diabetic foot ulcers (DFUs), we conducted both database searches (PubMed, MEDLINE, EMBASE, CENTRAL, and Web of Science) and reference searches for randomised controlled trials from the inception of databases to 30 January 2020. Two reviewers independently scrutinised the trials, extracted data, and assessed the quality of trials. The primary outcome was the proportion of complete healing. The secondary outcomes were mean time to complete healing and adverse events. A subgroup analysis was performed by different administration routes. Statistical analyses were performed in RevMan 5.3. The time to complete healing Kaplan-Meier curves was pooled in the R software. Of the 156 citations, 9 trials (720 participants) met eligibility criteria and were included. The rhEGF achieved a higher complete healing rate than placebo (OR: 2.79, [95% CI: 1.99, 3.99]). The rhEGF also significantly shorten complete healing time (MD: -14.10 days, [95% CI: -18.03, -10.16]). Subgroup analysis showed that topical application was superior to intralesional injection, but that may be because of different ulcer severity they included. No significant difference was shown in adverse events. Results were coherent with sensitivity analyses. Therefore, rhEGF is an effective and safe treatment for DFUs.
Identifiants
pubmed: 32343054
doi: 10.1111/iwj.13377
pmc: PMC7948637
doi:
Substances chimiques
Epidermal Growth Factor
62229-50-9
Types de publication
Journal Article
Meta-Analysis
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
1062-1073Informations de copyright
© 2020 Medicalhelplines.com Inc and John Wiley & Sons Ltd.
Références
Int J Low Extrem Wounds. 2016 Jun;15(2):120-5
pubmed: 27151755
N Engl J Med. 2017 Jun 15;376(24):2367-2375
pubmed: 28614678
JAMA. 2019 Jan 1;321(1):114
pubmed: 30620372
Lancet. 2005 Nov 12;366(9498):1719-24
pubmed: 16291066
J Nat Sci Biol Med. 2014 Jul;5(2):273-7
pubmed: 25097397
Diabet Med. 2016 Nov;33(11):1493-1498
pubmed: 26666583
BMJ. 2009 Jul 21;339:b2535
pubmed: 19622551
Cochrane Database Syst Rev. 2015 Oct 28;(10):CD008548
pubmed: 26509249
Int Wound J. 2020 Aug;17(4):1062-1073
pubmed: 32343054
Int J Low Extrem Wounds. 2020 Jun;19(2):158-164
pubmed: 31878810
Ann N Y Acad Sci. 2018 Jan;1411(1):153-165
pubmed: 29377202
Int J Environ Res Public Health. 2019 Jul 19;16(14):
pubmed: 31331038
Diabetes Care. 2003 Jun;26(6):1856-61
pubmed: 12766123
Diabetes Care. 2003 May;26(5):1435-8
pubmed: 12716801
Diabet Med. 2019 Aug;36(8):995-1002
pubmed: 31004370
Trials. 2007 Jun 07;8:16
pubmed: 17555582
Diabetes Res Clin Pract. 2018 Aug;142:335-344
pubmed: 29902542
Int Wound J. 2009 Dec;6(6):432-43
pubmed: 20051095
Int Wound J. 2006 Sep;3(3):232-9
pubmed: 16984579
Exp Ther Med. 2019 Mar;17(3):1643-1648
pubmed: 30783432
Diabetes Res Clin Pract. 2007 Dec;78(3):405-11
pubmed: 17655964
Wound Repair Regen. 2014 Jul-Aug;22(4):497-503
pubmed: 25041620
Int Wound J. 2015 Aug;12(4):373-4
pubmed: 26138717
Ann Vasc Surg. 2020 Jan;62:442-451
pubmed: 31394225
Exp Ther Med. 2018 Jun;15(6):5365-5370
pubmed: 29904416